Current MED Diag & Treatment

Skyscape Medpresso Inc



Incorporate the latest research findings into your clinical practice with the #1 annually updated guide to internal medicine. Download the FREE app and view selected topics (Approximately 10% of the content is viewable in the free app and tapping on the locked topic will launch the in-app purchase screen).HERE IS WHY CMDT IS THE ULTIMATE CLINICAL COMPANION:- Medical advances up to time of annual publication- Detailed presentation of primary care topics, including gynecology, obstetrics, dermatology, ophthalmology, otolaryngology, psychiatry, neurology, toxicology, urology, geriatrics, orthopedics, women’s health, preventive medicine, and palliative care- Concise format, facilitating efficient use in any practice setting- More than 1000 diseases and disorders- Annual update on HIV/AIDS and other newly emerging infections.- Specific disease prevention information- Easy access to medication dosages, with trade names indexed and costs updated in each edition- Recent references, with unique identifiers (PubMed, PMID numbers) for rapid downloading of article abstracts and, in some instances, full-text reference articlesNEW TO THIS EDITION OF CMDT :- Substantial revision of acute and chronic (cancer and noncancer) pain management and benefits and risks of opioid use- New chapter on Lesbian, Gay, Bisexual, & Transgender Health- New recommendations for initial empiric antibiotic treatment for hospital-acquired and ventilator-associated pneumonia- New discussion of physician-assisted death- New Table outlining criteria to rule out pulmonary embolism- 2016 CHEST Guideline and Expert Panel Report detailing anticoagulation treatment recommendations in patients with cancer and noncancer diagnoses- New categorization of pressure injuries (formerly pressure ulcers)- New treatment recommendations from American College of Cardiology/American Heart Association and the European Society of Cardiology for patients who have heart failure with reduced ejection fraction- Rewritten section on occlusive cerebrovascular disease- Rewritten section on shock- New information on treatments for chronic lymphocytic leukemia and Hodgkin lymphoma- Updated treatment options for plasma cell myeloma (formerly multiple myeloma)- New FDA-approved medication for Clostridium difficile infection- Updated treatment options for hepatitis C infection- New FDA-approved medications for ulcerative colitis and Crohn disease- New pharmacologic treatment for hormone receptor–positive breast cancer- Rewritten section on attention-deficit/hyperactivity disorder- New section on autism spectrum disorder- Extensive revision of Endocrine Disorders chapter- Updated recommendations for preexposure prophylaxis of HIV infection- Substantial revision of the Viral & Rickettsial Infections chapterNew antiemetic combination medication for chemotherapy-induced nausea- New therapy options for castration-resistant prostate cancer- New FDA-approved medication for bladder cancerAbout the Authors:Maxine A. Papadakis, MDProfessor of Medicine, EmeritusDepartment of MedicineUniversity of California, San FranciscoStephen J. McPhee, M.D.Professor of Medicine, EmeritusDivision of General Internal MedicineDepartment of MedicineUniversity of California, San Francisco